Search LUNG
Pulmonx Corp
Nasdaq · CIK 1127537
Last close1.83
Daily change-0.08 (-4.19%)
10 Years gain-95.34%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
LUNG · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
50.3Momentum
100.0Acceleration
62.5Confidence
91.0Annual Revenue8
Quarterly Revenue25
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth16.7 / 25
Quality17.4 / 25
Capital Efficiency0.0 / 20
Balance Sheet13.5 / 15
Shareholder Economics2.8 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 1.9956 percentage points.
Operating leverageOperating margin improved by 13.5478 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
ROIC declining · MEDIUMROIC declined by 8.7684 percentage points.
Key Metrics
Revenue Growth TTM7.44%OK
Revenue CAGR 3Y19.03%OK
Gross Margin75.58%OK
Operating Margin-57.73%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-59.6%OK
Incremental Operating Margin 3Y3.41%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y6.29%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $90.50M | $67.14M | -$53.66M | -$32.38M | -$32.83M | 74.19% | -59.3% | -36.28% | -115.29% | 40.69M |
| 2025 FY Dec 31, 2024 | $83.79M | $62.00M | -$57.70M | -$31.54M | -$32.98M | 74% | -68.87% | -39.37% | -73.47% | 39.11M |
| 2024 FY Dec 31, 2023 | $68.68M | $50.75M | -$61.94M | -$37.61M | -$38.42M | 73.9% | -90.19% | -55.94% | -95.75% | 37.97M |
| 2023 FY Dec 31, 2022 | $53.66M | $39.87M | -$58.64M | -$45.08M | -$46.40M | 74.29% | -109.27% | -86.47% | -152.36% | 37.1M |
| 2022 FY Dec 31, 2021 | $48.42M | $35.63M | -$47.30M | -$41.39M | -$45.06M | 73.59% | -97.7% | -93.07% | -175.64% | 36.13M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $88.70M | sum latest 4 fiscal quarters Revenue | OK | 0001127537-26-000039, 0001127537-25-000059 |
| Revenue Growth TTM | 7.44% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001127537-26-000039, 0001127537-25-000059 |
| Revenue CAGR 3Y | 19.03% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001127537-26-000015 |
| Revenue CAGR 5Y | 22.55% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001127537-26-000015 |
| Gross Profit CAGR 3Y | 18.98% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001127537-26-000015 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001127537-26-000039, 0001127537-25-000059 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 75.58% | Gross Profit / Revenue | OK | 0001127537-26-000039, 0001127537-25-000059 |
| Operating Margin | -57.73% | Operating Income / Revenue | OK | 0001127537-26-000039, 0001127537-25-000059 |
| ROIC | -59.6% | NOPAT / Average Invested Capital | OK | 0001127537-26-000039, 0001127537-25-000059 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001127537-26-000039 |
| Current Ratio | 4.32x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 1.49x | (Cash + Short-term Investments) / Total Debt | OK | 0001127537-26-000039 |
| Revenue per Diluted Share | $2.09 | Revenue / Diluted Shares | OK | 0001127537-26-000039, 0001127537-25-000059 |